Rhumbline Advisers Has $49 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Rhumbline Advisers increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 1.0% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 181,463 shares of the biopharmaceutical company's stock after acquiring an additional 1,885 shares during the period. Rhumbline Advisers owned 0.14% of Alnylam Pharmaceuticals worth $48,999,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the business. Summit Global Investments bought a new stake in Alnylam Pharmaceuticals during the 1st quarter valued at approximately $849,000. GAMMA Investing LLC boosted its stake in Alnylam Pharmaceuticals by 30,759.4% during the 1st quarter. GAMMA Investing LLC now owns 166,332 shares of the biopharmaceutical company's stock valued at $44,913,000 after purchasing an additional 165,793 shares during the period. Versant Capital Management Inc boosted its stake in Alnylam Pharmaceuticals by 76.8% during the 1st quarter. Versant Capital Management Inc now owns 336 shares of the biopharmaceutical company's stock valued at $91,000 after purchasing an additional 146 shares during the period. California State Teachers Retirement System boosted its stake in Alnylam Pharmaceuticals by 2.6% during the 4th quarter. California State Teachers Retirement System now owns 196,362 shares of the biopharmaceutical company's stock valued at $46,206,000 after purchasing an additional 5,037 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Alnylam Pharmaceuticals by 94.7% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 12,566 shares of the biopharmaceutical company's stock valued at $2,957,000 after purchasing an additional 6,112 shares during the period. Institutional investors own 92.97% of the company's stock.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the firm's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the sale, the chief executive officer now directly owns 48,948 shares of the company's stock, valued at $14,978,088. This trade represents a 28.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ALNY has been the subject of several recent analyst reports. Chardan Capital increased their target price on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Royal Bank of Canada increased their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research note on Friday, March 21st. Scotiabank increased their target price on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research note on Monday, March 31st. Wall Street Zen upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $319.17.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock traded up $2.69 during midday trading on Thursday, hitting $308.00. 761,194 shares of the company were exchanged, compared to its average volume of 929,505. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The firm has a market cap of $40.16 billion, a P/E ratio of -141.93 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a 52 week low of $147.25 and a 52 week high of $310.23. The firm has a 50 day simple moving average of $262.51 and a 200-day simple moving average of $256.16.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.16) EPS. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.